Swan Capital’s Halozyme HALO Stock Holding History

Swan Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18	Closed	-$1.03K	–	398
2024 Q3	$1.03K	Buy	+18	New	+$1.03K	﹤0.01%	263

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Swan Capital's HALO Position: Q4 2024 in Review

Swan Capital sold out of Halozyme (HALO) in Q4 2024, closing a stake of 18 shares — an estimated $1.03K sold.

Swan Capital first reported a position in HALO in Q3 2024 and held it in 1 quarter. The position peaked at $1.03K in Q3 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

Swan Capital reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
Swan Capital sold 18 Halozyme shares in Q4 2024, an estimated $1.03K.
Swan Capital first reported a position in Halozyme in Q3 2024 and held it in 1 quarter.
Swan Capital's Halozyme position peaked at $1.03K in Q3 2024.
508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Swan Capital's 13F filing for Q4 2024, filed 25 Feb 2025.